Patients with advanced head and neck cancer are needed for a study to research the combination of an experimental drug and radiation therapy

IRB/UVA Tracking #
Principal Investigator
Varinder Kaur
Olusegun Bamidele Adelaja
Contact Email
Contact Phone
Official Trial Title
Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin (NRG-HN004)
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and have advanced head and neck cancer. The purpose of this study to evaluate the combination of an experimental drug (durvalumab) with radiation therapy in patients with advanced head and neck cancer. The safety and effects of the experimental drug combination will be evaluated for this study.

Participation is approximately 2-6 months of treatment or possibly longer, with a longer follow-up via a clinic visit or a phone call to keep track of how you’re doing. Study specific test will be provided at no cost to you.

Additional information can be found here:


You will not receive compensation for this study. Reimbursement: You will not receive reimbursement for this study.